Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2014

View Archived Issues

SBI Pharmaceuticals and the University of Oxford to begin phase II trial of 5-ALA

Theraclone forms agreement with Gilead Sciences for neutralizing HIV antibodies

Jenken completes sale of assets to TaiwanJ

Nanosyn establishes research services agreement with Forma Therapeutics

Cloud Pharmaceuticals receives grant for in silico drug discovery

Rosetta Genomics enters two microRNA collaborations

Proteostasis Therapeutics achieves preclinical milestone in Biogen Idec collaboration

Advaxis and University of Pennsylvania modify Listeria technology agreement

Cynata engages University of Wisconsin-Madison to develop stem cell preservation technology

Phase II results presented for siRNA drug for the prophylaxis of DGF

Mitsubishi Tanabe Pharma recaps developments of first quarter of fiscal 2014

Prevention of ischemia/reperfusion injury by blockade of the NF-kappa-B pathway with SPA-0355

Eleven Biotherapeutics patents new anti-PCSK9 MAbs

New podophyllotoxin derivatives patented by Advanomics for cancer

New inhibitors of HCV NS5B polymerase disclosed by Bristol-Myers Squibb

Bristol-Myers Squibb patents novel ROCK inhibitors

Sumitomo Dainippon Pharma reviews progress of first quarter of fiscal 2014

Flexion signs licensing agreement with SwRI for microsphere manufacturing technologies

Redbiotec and GE Healthcare collaborate to develop novel manufacture process for CMV vaccine

EMA accepts Eisai's request for accelerated assessment of lenvatinib

Meda to acquire Rottapharm

FDA advisory committee recommends approval of HyQvia for primary immunodeficiency

First-in-human trial results for anti-CD40 MAb CFZ-533 as an immunosuppressant

Taiho Pharmaceutical terminates phase III trial of TSU-68 in hepatocellular carcinoma

CytoDyn reports interim data from phase IIb trial of PRO-140 in patients with HIV

Intravenous posaconazole recommended for approval in E.U.

Asahi Kasei Pharma files regulatory submission for Xiaflex in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...